509 related articles for article (PubMed ID: 32967374)
1. The Rationale of Neprilysin Inhibition in Prevention of Myocardial Ischemia-Reperfusion Injury during ST-Elevation Myocardial Infarction.
Bellis A; Mauro C; Barbato E; Di Gioia G; Sorriento D; Trimarco B; Morisco C
Cells; 2020 Sep; 9(9):. PubMed ID: 32967374
[TBL] [Abstract][Full Text] [Related]
2. The Rationale for Angiotensin Receptor Neprilysin Inhibitors in a Multi-Targeted Therapeutic Approach to COVID-19.
Bellis A; Mauro C; Barbato E; Trimarco B; Morisco C
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33203141
[TBL] [Abstract][Full Text] [Related]
3. Effects of sacubitril/valsartan on neprilysin targets and the metabolism of natriuretic peptides in chronic heart failure: a mechanistic clinical study.
Nougué H; Pezel T; Picard F; Sadoune M; Arrigo M; Beauvais F; Launay JM; Cohen-Solal A; Vodovar N; Logeart D
Eur J Heart Fail; 2019 May; 21(5):598-605. PubMed ID: 30520545
[TBL] [Abstract][Full Text] [Related]
4. Aliskiren reduces myocardial ischemia-reperfusion injury by a bradykinin B2 receptor- and angiotensin AT2 receptor-mediated mechanism.
Koid SS; Ziogas J; Campbell DJ
Hypertension; 2014 Apr; 63(4):768-73. PubMed ID: 24420538
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the Efficacy and Safety of Sacubitril/Valsartan versus Ramipril in Patients With ST-Segment Elevation Myocardial Infarction.
Rezq A; Saad M; El Nozahi M
Am J Cardiol; 2021 Mar; 143():7-13. PubMed ID: 33417876
[TBL] [Abstract][Full Text] [Related]
6. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.
Hubers SA; Brown NJ
Circulation; 2016 Mar; 133(11):1115-24. PubMed ID: 26976916
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy.
von Lueder TG; Wang BH; Kompa AR; Huang L; Webb R; Jordaan P; Atar D; Krum H
Circ Heart Fail; 2015 Jan; 8(1):71-8. PubMed ID: 25362207
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin receptor neprilysin inhibition provides superior cardioprotection compared to angiotensin converting enzyme inhibition after experimental myocardial infarction.
Kompa AR; Lu J; Weller TJ; Kelly DJ; Krum H; von Lueder TG; Wang BH
Int J Cardiol; 2018 May; 258():192-198. PubMed ID: 29544929
[TBL] [Abstract][Full Text] [Related]
9. Myocardial reperfusion injury: looking beyond primary PCI.
Fröhlich GM; Meier P; White SK; Yellon DM; Hausenloy DJ
Eur Heart J; 2013 Jun; 34(23):1714-22. PubMed ID: 23536610
[TBL] [Abstract][Full Text] [Related]
10. Reperfusion in STEMI patients: still a role for cardioprotection?
Ottani F; Limbruno U; Latini R; Misuraca L; Galvani M
Minerva Cardioangiol; 2018 Aug; 66(4):452-463. PubMed ID: 29589674
[TBL] [Abstract][Full Text] [Related]
11. Dual Angiotensin Receptor and Neprilysin Inhibition with Sacubitril/Valsartan in Chronic Systolic Heart Failure: Understanding the New PARADIGM.
Lillyblad MP
Ann Pharmacother; 2015 Nov; 49(11):1237-51. PubMed ID: 26175499
[TBL] [Abstract][Full Text] [Related]
12. [Mechanism of cardioprotection against ischemia/reperfusion injury by valsartan: an experiment with isolated rat hearts].
Zhang YJ; Bai XJ; Qi ZM; Wang HX
Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(47):3350-3. PubMed ID: 16409843
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic, pharmacodynamic, and antihypertensive effects of the neprilysin inhibitor LCZ-696: sacubitril/valsartan.
Chrysant SG
J Am Soc Hypertens; 2017 Jul; 11(7):461-468. PubMed ID: 28652105
[TBL] [Abstract][Full Text] [Related]
14. Effects of dual angiotensin type 1 receptor/neprilysin inhibition vs. angiotensin type 1 receptor inhibition on target organ injury in the stroke-prone spontaneously hypertensive rat.
Rubattu S; Cotugno M; Forte M; Stanzione R; Bianchi F; Madonna M; Marchitti S; Volpe M
J Hypertens; 2018 Sep; 36(9):1902-1914. PubMed ID: 29916993
[TBL] [Abstract][Full Text] [Related]
15. Combined Angiotensin Receptor-Neprilysin Inhibitors Improve Cardiac and Vascular Function Via Increased NO Bioavailability in Heart Failure.
Trivedi RK; Polhemus DJ; Li Z; Yoo D; Koiwaya H; Scarborough A; Goodchild TT; Lefer DJ
J Am Heart Assoc; 2018 Mar; 7(5):. PubMed ID: 29502102
[TBL] [Abstract][Full Text] [Related]
16. Neprilysin inhibition with sacubitril/valsartan in the treatment of heart failure: mortality bang for your buck.
Ansara AJ; Kolanczyk DM; Koehler JM
J Clin Pharm Ther; 2016 Apr; 41(2):119-27. PubMed ID: 26992459
[TBL] [Abstract][Full Text] [Related]
17. Mineralocorticoid receptor antagonist pre-treatment and early post-treatment to minimize reperfusion injury after ST-elevation myocardial infarction: The MINIMIZE STEMI trial.
Bulluck H; Fröhlich GM; Nicholas JM; Mohdnazri S; Gamma R; Davies J; Sirker A; Mathur A; Blackman D; Garg P; Moon JC; Greenwood JP; Hausenloy DJ
Am Heart J; 2019 May; 211():60-67. PubMed ID: 30893577
[TBL] [Abstract][Full Text] [Related]
18. Editor's Choice- Pathophysiology and therapy of myocardial ischaemia/reperfusion syndrome.
Rossello X; Lobo-Gonzalez M; Ibanez B
Eur Heart J Acute Cardiovasc Care; 2019 Aug; 8(5):443-456. PubMed ID: 31172789
[TBL] [Abstract][Full Text] [Related]
19. Neprilysin inhibition to treat heart failure: a tale of science, serendipity, and second chances.
McMurray JJ
Eur J Heart Fail; 2015 Mar; 17(3):242-7. PubMed ID: 25756942
[TBL] [Abstract][Full Text] [Related]
20. Angiotensin Receptor-Neprilysin Inhibition.
Havakuk O; Elkayam U
J Cardiovasc Pharmacol Ther; 2017 Jul; 22(4):356-364. PubMed ID: 28587583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
